Analysis of the prognostic role of plasmatic K-ras mutations in advanced non-small cell lung cancer (NSCLC) patients

被引：0
|
作者：
Sirera, R.
Camps, C.
Berrocal, A.
Munoz-Navarro, M.
Garcia-Gomez, R.
Vinolas, N.
Artal, A.
Guillot, M.
Taron, M.
Rosell, R.
机构：
[1] Hosp Gen Valencia, Valencia, Spain
[2] Hosp Gregorio Maranon, Madrid, Spain
[3] Hosp Clin Barcelona, Barcelona, Spain
[4] Hosp Miguel Servet, Zaragoza, Spain
[5] Hosp Son Dureta, Palma De Mallorca, Spain
[6] Hosp Badalona Germans Trias & Pujol, Badalona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
18009
引用
收藏
页数：1
相关论文
共 50 条
  • [31] The prognostic and predictive role of hyponatremia in patients with advanced non-small cell lung cancer (NSCLC) with bone metastases
    S. Rinaldi
    M. Santoni
    G. Leoni
    I. Fiordoliva
    G. Marcantognini
    T. Meletani
    G. Armento
    D. Santini
    T. Newsom-Davis
    M. Tiberi
    F. Morgese
    M. Torniai
    M. Bower
    Rossana Berardi
    Supportive Care in Cancer, 2019, 27 : 1255 - 1261
  • [32] Across the Universe of K-Ras Mutations in Non-Small-Cell-Lung Cancer
    Piva, Sheila
    Ganzinelli, Monica
    Garassino, Marina Chiara
    Caiola, Elisa
    Farina, Gabriella
    Broggini, Massimo
    Marabese, Mirko
    CURRENT PHARMACEUTICAL DESIGN, 2014, 20 (24) : 3933 - 3943
  • [33] Epidermal Growth Factor Receptor and K-Ras mutations in patients with Non Small Cell Lung Cancer
    Mugalaasi, Hood
    Davies, J.
    Medley, L.
    Talbot, D.
    Butler, R.
    Brito, R.
    JOURNAL OF MEDICAL GENETICS, 2009, 46 : S89 - S89
  • [34] k-RAS mutations in non-small cell lung cancer patients treated with TKIs among smokers and non-smokers: a meta-analysis
    Jiang, Ai-Gui
    Lu, Hui-Yu
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2016, 20 (02): : 124 - 129
  • [35] Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations
    Park, In Hae
    Kim, Jin Young
    Jung, Jae In
    Han, Ji-Youn
    INVESTIGATIONAL NEW DRUGS, 2010, 28 (06) : 791 - 799
  • [36] Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations
    In Hae Park
    Jin Young Kim
    Jae In Jung
    Ji-Youn Han
    Investigational New Drugs, 2010, 28 : 791 - 799
  • [37] Association of epidermal growth factor receptor and K-Ras mutations with smoking history in non-small cell lung cancer patients
    Baykara, Onur
    Tansarikaya, Merve
    Demirkaya, Ahmet
    Kaynak, Kamil
    Tanju, Serhan
    Toker, Alper
    Buyru, Nur
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2013, 5 (02) : 495 - 498
  • [38] Mutations in K-ras codon 12 detected in plasma DNA are not an indicator of disease in patients with non-small cell lung cancer
    Trombino, S
    Neri, M
    Puntoni, R
    Angelini, C
    Loprevite, M
    Cesario, A
    Granone, P
    Imperatori, A
    Dominioni, L
    Ardizzoni, A
    Filiberti, R
    Russo, P
    CLINICAL CHEMISTRY, 2005, 51 (07) : 1313 - 1314
  • [39] Smoking and prognostic factors in advanced non-small cell lung cancer (NSCLC)
    Altug, S.
    Li, C.
    Marek, M.
    Guclu, S.
    Kim, Y.
    Meshref, M.
    Qin, S.
    Krejcy, K.
    Reece, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [40] A Phase II Study of Sorafenib in Patients with Locally Advanced And/or Metastatic (stage IIIB or IV) Non-small Cell Lung Cancer (NSCLC) with a K-Ras Mutation
    Dingemans, A. M.
    Mellema, W. W.
    Groen, H. J. M.
    van Wijk, A.
    Burgers, S.
    Kunst, P. W. A.
    Thunnissen, F. B.
    Heideman, D. A. M.
    Smit, E. F.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : 14 - 14
12345